TY - JOUR T1 - NG2 and GFAP co-expression after differentiation in cells transfected with mutant GFAP and in undifferentiated glioma cells JO - Neurología (English Edition) T2 - AU - Gómez-Pinedo,U. AU - Sirerol-Piquer,S. AU - Durán-Moreno,M. AU - Matias-Guiu,J.A. AU - Barcia,J.A. AU - García-Verdugo,J.M. AU - Matias-Guiu,J. SN - 21735808 M3 - 10.1016/j.nrleng.2017.11.001 DO - 10.1016/j.nrleng.2017.11.001 UR - https://www.elsevier.es/en-revista-neurologia-english-edition--495-articulo-ng2-gfap-co-expression-after-differentiation-S2173580819300781 AB - IntroductionAlexander disease is a rare disorder caused by mutations in the gene coding for glial fibrillary acidic protein (GFAP). In a previous study, differentiation of neurospheres transfected with these mutations resulted in a cell type that expresses both GFAP and NG2. ObjectiveTo determine the effect of molecular marker mutations in comparison to undifferentiated glioma cells simultaneously expressing GFAP and NG2. MethodsWe used samples of human glioblastoma (GBM) and rat neurospheres transfected with GFAP mutations to analyse GFAP and NG2 expression after differentiation. We also performed an immunocytochemical analysis of neuronal differentiation for both cell types and detection of GFAP, NG2, vimentin, Olig2, and caspase-3 at 3 and 7 days from differentiation. ResultsBoth the cells transfected with GFAP mutations and GBM cells showed increased NG2 and GFAP expression. However, expression of caspase-3-positive cells was found to be considerably higher in transfected cells than in GBM cells. ConclusionsOur results suggest that GFAP expression is not the only factor associated with cell death in Alexander disease. Caspase-3 expression and the potential role of NG2 in increasing resistance to apoptosis in cells co-expressing GFAP and NG2 should be considered in the search for new therapeutic strategies for the disease. ER -